A61P 25/36
Opioid-abuse
A61P25/36 (Opioid-abuse) appears on 2,498 US grants and 4,141 published applications in this corpus.
Search patents in A61P- Granted patents
- 2,498
- Published applications
- 4,141
- Assignees
- 1,000
- Inventors
- 5,778
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 13 | 0 |
| 1998 | 8 | 0 |
| 1999 | 11 | 0 |
| 2000 | 17 | 0 |
| 2001 | 34 | 9 |
| 2002 | 46 | 74 |
| 2003 | 54 | 151 |
| 2004 | 69 | 191 |
| 2005 | 56 | 191 |
| 2006 | 84 | 211 |
| 2007 | 99 | 224 |
| 2008 | 102 | 274 |
| 2009 | 129 | 272 |
| 2010 | 153 | 355 |
| 2011 | 159 | 246 |
| 2012 | 185 | 215 |
| 2013 | 161 | 186 |
| 2014 | 159 | 163 |
| 2015 | 149 | 212 |
| 2016 | 129 | 191 |
| 2017 | 137 | 154 |
| 2018 | 113 | 139 |
| 2019 | 87 | 125 |
| 2020 | 76 | 132 |
| 2021 | 63 | 93 |
| 2022 | 53 | 96 |
| 2023 | 38 | 76 |
| 2024 | 42 | 74 |
| 2025 | 45 | 51 |
| 2026 | 23 | 36 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Cobalt-porphyrin complexes for the inactivation of the biological activity of opioids15 Sep 2026US 12,734,146 B2The Government of the United States of America, as represented by the Secretary of the Navy
- Abuse-resistant pharmaceutical composition for the treatment of opioid dependence11 Aug 2026US 12,702,666 B2Edenbridge Pharmaceuticals, LLC
- Tetrahydroisoquinoline compound as potassium channel modulator and preparation and application thereof11 Aug 2026US 12,703,687 B2Shanghai Zhimeng Biopharma, Inc.
- Modified release formulation for (-)-(3AR,4S,7AR)-4-hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester16 Jun 2026US 12,653,807 B2Novartis AG
- Formulations and treatment methods16 Jun 2026US 12,653,819 B2Camurus AB
- Rapid induction with monthly injectable buprenorphine extended-release8 Oct 2026US 2026/0306480 A1Indivior UK Limited
- Rapid induction with monthly injectable buprenorphine extended-release8 Oct 2026US 2026/0306481 A1Indivior UK Limited
- Combinations including methocinnamox24 Sep 2026US 2026/0284035 A1Board of Regents, The University of Texas System
- Oral compositions containing methocinnamox24 Sep 2026US 2026/0284036 A1Board of Regents, The University of Texas System
- Methods for the non-toxic treatment for opioid drug withdrawal combining noribogaine and cannabinoids24 Sep 2026US 2026/0284072 A1Demerx, Inc.
Most cited
By later US patents
- Method of preventing abuse of opioid dosage forms391US 6,228,863 B1Euro-Celtique S. A. · 2001
- Tamper-resistant oral opioid agonist formulations343US 6,696,088 B2Euro-Celtique S. A. · 2004
- Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance277US 5,321,012 AVirginia Commonwealth University Medical College · 1994
- Methods and compositions for deterring abuse of opioid containing dosage forms267US 7,201,920 B2Acura Pharmaceuticals, Inc. · 2007
- Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant257US 7,332,182 B2Purdue Pharma L. P. · 2008